Sundrug - Company History

Sundrug began in December 1957 as a single five-tsubo pharmacy — barely sixteen square metres — that Yukimasa Tada opened in the Chitose-Funabashi district of Setagaya, Tokyo, and named the Futaba Pharmacy. Drug retailing in post-war Japan was overwhelmingly a corner-shop trade: individual apothecaries, almost none of them running more than one store. Tada, born in 1927, set out to build something larger, and in April 1965 reorganized the business as Sundrug Ltd., beginning — from that base — to open a chain.

In July 1980 the limited company was recast as a joint-stock corporation, Sundrug Co., Ltd., and that December it opened a suburban drugstore in Hachioji, on Tokyo’s western fringe. The move away from the shopping-street pharmacy toward a car-oriented, American-style format — a parking lot out front, medicines, cosmetics and daily goods stacked in volume — set the template Sundrug would run on for decades. Twenty-three years after its founding, the corner apothecary had become a multi-store chain, still led by the founder, who would hold the presidency until 1994.

What set Sundrug apart was not a product but a cost structure, and it was built early. From February 1985 the company put its sales and ordering on line; in December 1986 it opened a distribution centre with an automated picking system in Kunitachi; and by November 1991 it had installed point-of-sale registers across every store. Full computer systems were not yet common in the drugstore trade, and for a chain of this size to invest ahead of the field — while the founder still ran it — was unusual.

The pay-off was structural. Logistics and POS let Sundrug hold its labour and overhead ratios well below the industry norm, and that discipline, more than any single store, is the source of the low selling-and-administrative-expense ratio the company became known for. A drugstore earns by pairing high-margin medicines with low-margin food and sundries; Sundrug supported that arithmetic with its systems, lifting turnover per store until even loss-leader pricing paid. By the early 1990s single-company sales had reached about $206.9M (¥23bn), and the cost machine that would carry the next two decades was essentially in place — ready for a public listing.

In August 1994 Sundrug registered its shares over the counter, and in the same year the founder handed the presidency to Tatsuro Saizu, an executive vice-president and the first leader from outside the founding family. Saizu inherited consolidated sales of about $272.9M (¥28bn) and, by the time he moved up to chairman in 2013, had multiplied them roughly sixteen-fold to about $4.2B (¥448bn), with operating profit up more than twelvefold. The twenty consecutive years of rising sales and profit that opened his tenure became a record spoken of across Japanese retail.

The growth had two engines. One was a roll-up of regional operators — Taisei Home Aid in Chiba (1996), then chains in Tochigi, Kanagawa, Niigata, Aichi and Hokkaido — knitted together through franchising and acquisition rather than imposed from head office, so that Sundrug spread nationwide by networking local businesses. The other was the low-cost operation itself, layered on the 1980s logistics and POS base: the company held its selling-and-administrative ratio under 20% and, by 2009, posted an ordinary-profit margin of 6.5%.

The larger strategic move came in December 2009, when Sundrug bought Direx — a discount-store chain across Kyushu and the Chugoku-Shikoku region, with annual sales near $958M (¥90bn) — for about $101.6M (¥10bn). Direx’s strength in fresh food and large suburban stores let Sundrug split its map: drugstores for dense city markets, fresh-food discount stores for thinner rural ones. The purchase turned Sundrug into a two-format company. Succession, though, grew turbulent — Saizu passed the presidency to Motoya Akao in 2013, but Akao died in office in 2018, forcing Saizu to hold the post again until Koji Sadakata took over in May 2019.

Koji Sadakata took the presidency in 2019 as the drugstore trade entered a decade of mergers. In October 2021 Matsumotokiyoshi and Cocokara Fine combined into Matsukiyo Cocokara & Company, with sales of about $9.1B (¥1tn); in February 2024 Welcia and Tsuruha announced a tie-up aimed at roughly $13.2B (¥2tn) by the end of 2027. Sundrug, with consolidated sales near $5.4B (¥802bn) in the year to March 2025, sat apart from these giants.

Rather than merge, Sadakata chose a middle path — his own store openings plus loose capital alliances. In November 2023 Sundrug signed a capital tie-up with BCPE Knight Holdings Cayman, and in February 2024 it took an indirect 33.4% stake in Kansai-based Kirindo Holdings, making it an equity-method affiliate. Keeping Kirindo — whose store territory barely overlaps Sundrug’s — at an equity stake rather than a full takeover was deliberate: preserve each side’s independence while cooperating on private-label development, and signal no rush to consolidate.

Sundrug’s medium-term plan targets $6.3B (¥1tn) in sales and 1,750 stores by March 2026 — a steep reach that organic growth alone will not close, to be bridged by deeper cooperation with Kirindo and further acquisitions. Yet the discipline holds: the year to March 2025 marked a twenty-third straight annual dividend increase, and net profit had risen two-and-a-half-fold over the prior thirteen years — grown, in Sundrug’s fashion, by widening profit itself rather than by paying out a larger share. The cost-first, high-margin model that Tatsuro Saizu hardened has carried into Sadakata’s independent, mid-sized course through a consolidating trade.